Table 2.
Frequency of Breakdown of RAS and BRAF Mutations Detected in Colorectal Cancer Patients
| Mutation Status | No. of Cases | Proportion Among 302 Cases |
|---|---|---|
| WT RAS or BRAF | 142 | 47.0% |
| KRAS exon 2 mutant | 113 | 37.4% |
| p.G12S | 5 | 1.7% |
| p.G12C | 8 | 2.6% |
| p.G12R | 4 | 1.3% |
| p.G12D | 44 | 14.6% |
| p.G12 V | 23 | 7.6% |
| p.G12A | 6 | 2.0% |
| p.G12A, p.G12R | 1 | 0.3% |
| p.G13D | 20 | 6.6% |
| p.G12D, p.G13D | 2 | 0.7% |
| Other KRAS exon 2 mutant* | 0 | 0.0% |
| KRAS exon 3 mutant | 6 | 2.0% |
| p.A59E | 1 | 0.3% |
| p.Q61H | 5 | 1.7% |
| Other KRAS exon 3 mutant* | 0 | 0.0% |
| KRAS exon 4 mutant | 10 | 3.3% |
| p.K117N | 2 | 0.7% |
| p.A146T | 6 | 2.0% |
| p.A146P | 1 | 0.3% |
| p.A146V | 1 | 0.3% |
| NRAS exon 2 mutant | 6 | 2.0% |
| p.G12D | 4 | 1.3% |
| p.G12V | 2 | 0.7% |
| Other NRAS exon 2 mutants | 0 | 0.0% |
| NRAS exon 3 mutant | 8 | 2.6% |
| p.Q61K | 2 | 0.7% |
| p.Q61L | 5 | 1.7% |
| p.Q61R | 1 | 0.3% |
| Other NRAS exon 3 mutant† | 0 | 0.0% |
| NRAS exon 4 mutant‡ | 0 | 0.0% |
| BRAF V600E mutant | 18 | 6.0% |
*KRAS p.G13S, p.G13R, p.G13V, and p.G13A.
**KRAS p.A59T, p.A59G, p.Q61K, p.Q61E, p.Q61L, p.Q61P, and p.Q61R.
§RAS p.G12S, pG12C, p.G12R, and p.G12A.
†NRAS p.A59T, p.A59G, pQ61E, p.Q61P, and Q61H.
‡NRAS p.K117N, p.A146T, p.A146P, and p.A146V.